C. difficile 위험도


Usual doseUncomplicated UTIComplicated UTIBone & joint infectionUncomplicated pneumonia, SSTISevere gynecologic, intraabdominal infectionBacterial meningitisLife-threatening infection in immunocompromised patientsP. aeruginosa pneumonia in cystic fibrosis patients1-2 g IV q8-12h250 mg IV q12h500 mg IV q8-12h2 g IV q12h0.5-1 g IV q8h2 g IV q8h2 g IV q8h2 g IV q8h30-50 mg/kg IV q8h (max 6 g/d)

  • Age 0-4w 30 mg/kg IV q12h

  • Age 1m-12y 30-50 mg/kg IV q8h

  • Age >12y Refer to adult dose (max 6 g/d)

No dose adjustment

CrCl >50CrCl 31-50CrCl 16-30CrCl 6-15CrCl <5HDCAPDCRRTNo dose adjustment1 g IV q12h1 g IV q24h500 mg IV q24h500 mg IV q48hAdditional 1 g IV after HD500 mg IV q24h1.25 g q8h

General Information

Broad gram-negative coverage including Pseudomonas, generally used for nosocomial infections including post-neurosurgical meningitis, or other infections based on susceptibilities.

Notable lack of gram-positive activity versus other cephalosporins.

Monitor renal function in elderly patients, and when administered concomitantly with aminoglycoside antibiotics, especially with higher dosages of aminoglycosides or prolonged therapy.

Monitor prothrombin time.

Perform periodic susceptibility testing when clinically appropriate.


  • Diarrhea

  • Phlebitis

  • Injection site inflammation


  • Stevens-Johnson syndrome

  • Toxic epidermal necrolysis

  • Clostridium difficile colitis

  • Anaphylaxis

  • Seizure

  • Warfarin - increased risk of bleeding

  • Cholera vaccine, live

  • Combination oral contraceptives

  • Potential cross-reactivity with aztreonam based on side chain

Antimicrobial class: 3rd Generation Cephalosporin

Pregnancy category: B

Average serum half life: 2 hours

Biliary penetration: Moderate

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic


  • Elevated serum concentrations of ceftazidime as a result of renal impairment may lead to seizures, encephalopathy, coma, asterixis, neuromuscular excitability, or myoclonia; monitoring recommended and dosage adjustment necessary.

  • Use caution in penicillin-sensitive patients, as cross-hypersensitivity has been reported among beta-lactam antibiotics.

  • Use caution in individuals with a history of gastrointestinal disease, particularly colitis.

AAC 2017;61:e00464-17

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.